• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New LumiraDx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LMDX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LMDX

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for LumiraDx in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for LMDX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in LumiraDx. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/14/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/6/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/28/2023Raymond JamesLower TargetOutperform ➝ Outperform$1.00 ➝ $0.80
5/17/2023500.comReiterated RatingMaintains
5/17/2023Raymond JamesLower Target$1.50 ➝ $1.00
5/17/2023LADENBURG THALM/SH SHLower Target$3.80 ➝ $2.70
4/7/2023Raymond JamesLower TargetOutperform$2.00 ➝ $1.50
3/22/2023The Goldman Sachs GroupLower TargetNeutral$1.20 ➝ $0.85
3/22/2023Raymond JamesLower TargetOutperform$3.50 ➝ $2.00
12/19/2022The Goldman Sachs GroupInitiated CoverageNeutral
11/11/2022Raymond JamesLower TargetOutperform$4.00 ➝ $3.50
8/19/2022BTIG ResearchLower TargetBuy$7.00 ➝ $4.00
8/19/2022Raymond JamesLower TargetOutperform$7.00 ➝ $4.00
5/13/2022BTIG ResearchReiterated RatingBuy$8.00
5/12/2022LADENBURG THALM/SH SHLower Target$15.25 ➝ $14.00
3/11/2022Raymond JamesLower TargetOutperform$13.00 ➝ $9.00
11/15/2021Evercore ISIInitiated CoverageOutperform$20.00
11/12/2021BTIG ResearchReiterated RatingBuy$12.00
10/27/2021BTIG ResearchInitiated CoverageBuy$12.00
10/25/2021Raymond JamesInitiated CoverageOutperform
(Data available from 11/7/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/11/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/11/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/10/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/9/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/8/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/7/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
LumiraDx logo
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.01
Low: $0.01
High: $0.02

52 Week Range

Now: N/A

Volume

132,236,800 shs

Average Volume

56,745,219 shs

Market Capitalization

$5.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.73

Frequently Asked Questions

What sell-side analysts currently cover shares of LumiraDx?

The following sell-side analysts have issued stock ratings on LumiraDx in the last twelve months:
View the latest analyst ratings for LMDX.

What is the current price target for LumiraDx?

0 Wall Street analysts have set twelve-month price targets for LumiraDx in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for LumiraDx in the next year.
View the latest price targets for LMDX.

What is the current consensus analyst rating for LumiraDx?

LumiraDx currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LMDX.

What other companies compete with LumiraDx?

How do I contact LumiraDx's investor relations team?

LumiraDx's physical mailing address is 99 SUMMER STREET SUITE 200, BOSTON MA, 02110. The company's listed phone number is 354-640-0540 and its investor relations email address is [email protected]. The official website for LumiraDx is www.lumiradx.com. Learn More about contacing LumiraDx investor relations.